Last Updated: May 9, 2026

List of Excipients in Branded Drug CHILDRENS NASACORT ALLERGY 24HR


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for CHILDREN'S NASACORT ALLERGY 24HR

Last updated: March 3, 2026

What is the current excipient profile in CHILDREN'S NASACORT ALLERGY 24HR?

The product contains active ingredient triamcinolone acetonide nasal spray, with excipients including benzalkonium chloride as a preservative, ethanol, glycerol, and purified water. These excipients ensure the stability, delivery, and preservation of the nasal spray.

How do excipient choices impact formulation and stability?

Benzalkonium chloride acts as a preservative but can cause nasal irritation or discomfort in sensitive populations. Ethanol functions as a solvent and stabilizer, influencing shelf life and solubility. Glycerol serves as a humectant, maintaining moisture and preventing spray drying. These excipients are chosen to balance efficacy, safety, and shelf stability while minimizing adverse effects.

Are there opportunities to optimize excipient profiles?

Yes. Eliminating or reducing benzalkonium chloride could benefit patients with sensitivity, aligning with trends toward preservative-free formulations. Alternatives include replacing benzalkonium chloride with soft preservatives like preservative-free or aerosol delivery systems. Developing preservative-free versions could meet rising consumer demand for clean-label products and improve tolerability.

What commercial opportunities arise from excipient strategies?

  1. Preservative-Free Formulations: Marketed as gentler options, preservative-free nasal sprays command higher profit margins due to perceived safety and improved tolerability. They can be marketed to patients with sensitivities or allergies to traditional preservatives. The global nasal spray market, valued at USD 8.5 billion in 2022, indicates strong scope for premium products (Grand View Research, 2022).

  2. Alternative Delivery Systems: Unit-dose or multi-dose preservative-free delivery systems can reduce preservative use, expanding market reach.

  3. Regulatory Approvals and Patent Extension: Formulating new excipient profiles may qualify for regulatory exclusivity, extending product life cycles.

  4. Differentiation and Labeling: Marketing campaigns highlighting preservative-free status or reduced irritants enhance brand differentiation.

  5. Expansion into New Markets: Developing formulations tailored for sensitive populations or for regions with strict preservative regulations offers growth opportunities.

What are the challenges in reformulating or developing new excipient profiles?

Reformulation involves proving bioequivalence, maintaining stability, and ensuring safety and efficacy. Regulatory pathways require extensive testing, which entails costs and time. Patents covering existing formulations may limit immediate reformulation opportunities, requiring strategic planning.

How do regulatory environments influence excipient choices?

Regulatory agencies such as the FDA and EMA favor preservative-free products, especially in pediatric populations. Policies encourage minimizing preservative load in respiratory products due to potential toxicity and irritation, influencing R&D direction.

Summary table: Excipient considerations in CHILDREN'S NASACORT ALLERGY 24HR

Aspect Standard Formulation Trends and Opportunities
Preservatives Benzalkonium chloride Replace with preservative-free systems
Solvents Ethanol Use of alternative solvents for safety
Humectants Glycerol Maintain or replace with novel agents
Stability Adequate Focus on long-term stability without preservatives
Tolerability Moderate Improve via excipient reformulation

Key Takeaways

  • The excipient profile primarily uses benzalkonium chloride, ethanol, and glycerol, balancing stability and tolerability.
  • Trends favor reducing or eliminating preservatives, especially in pediatric products.
  • Preservative-free formulations offer a premium market opportunity, aligned with regulatory and consumer preferences.
  • Reformulation challenges include regulatory approval processes and maintaining product efficacy.
  • Market growth in nasal sprays provides a pathway for product differentiation through excipient innovation.

FAQs

Q1: How can preservatives like benzalkonium chloride impact pediatric nasal sprays?
They can cause nasal irritation and discomfort, especially in sensitive children. Reducing or eliminating these preservatives can improve tolerability.

Q2: Are preservative-free nasal sprays effective compared to traditional formulations?
Yes. Advances in delivery systems enable preservative-free sprays to maintain efficacy and stability comparable to preserved versions.

Q3: What regulatory hurdles exist for reformulating nasal sprays without preservatives?
Regulatory agencies require demonstration of bioequivalence, stability, and safety, often entailing extensive testing and documentation.

Q4: How does market demand influence excipient choices?
Increasing consumer awareness and regulatory pressures drive demand for products with fewer preservatives, creating opportunities for premium formulations.

Q5: Can excipient innovations extend patent life?
Potentially, if the reformulation results in novel, patentable excipient combinations or delivery systems, providing exclusivity benefits.


References

[1] Grand View Research. (2022). Nasal Spray Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Guidance for Industry: Drug Products Containing Less Than 1 Percent Ethanol.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.